Presented By Joshua Richter at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Test practice Multiplication. Multiplication 9x2.

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting

Phase Difference = Phase Difference = 0.05.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Slide 1 Presented By Edward Neuwelt at 2014 ASCO Annual Meeting.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

CCO Independent Conference Highlights

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Sham Mailankody at 2016 ASCO Annual Meeting

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Highlights: Myeloma Oral Session

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By John Bartlett at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

continued on next slide

Presented By Jason Fangusaro at 2017 ASCO Annual Meeting

Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

Future Strategies for Myeloma

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

continued on next slide

continued on next slide

Presented By James Rubenstein at 2016 ASCO Annual Meeting

الوسائل التعليمية الجمعة 14 آذار 2014 إعداد : هيثم شعيب.

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

Histamine H1 receptor antagonist

Children’s Hospital Update

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

II //II // \ Others Q.

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Presented By Steven Park at 2016 ASCO Annual Meeting

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Renal Function and Myeloma Therapeutics

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Spotlight on Monoclonal Antibodies in Multiple Myeloma

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

continued on next slide

Presented By Andrew Evens at 2016 ASCO Annual Meeting

continued on next slide

Presentation transcript:

Presented By Joshua Richter at 2016 ASCO Annual Meeting Updated Data from a Dose Finding Phase II Trial <br />of Single Agent Isatuximab (Anti-CD38 mAb) <br />in Relapsed/Refractory Multiple Myeloma Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 2 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 3 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 4 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 5 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting <br /> Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 7 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 8 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 9 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 10 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 11 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 12 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 13 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Slide 14 Presented By Joshua Richter at 2016 ASCO Annual Meeting

Isatuximab Infusion Duration Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Summary Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Joshua Richter at 2016 ASCO Annual Meeting Acknowledgments Presented By Joshua Richter at 2016 ASCO Annual Meeting